Efficacy of repeat transurethral resection in the treatment of non-muscle invasive bladder cancer

doi:10.3877/cma.j.issn.1674-3253.2022.06.006

Abstract

Abstract:

Objective

To analyze the clinical effect of repeat transurethral resection of bladder tumor (Re-TURBT) in the treatment of T_a and T₁ stage non-muscle invasive bladder cancer (NMIBC).

Methods

The clinical data of 86 patients with T_a and T₁ stage non-muscle invasive bladder cancer diagnosed in the Fifth Affiliated Hospital of Sun Yat-sen University from Feb. 2015 to Nov.2018 were retrospectivley analysed. Forty patients received only TURBT were as control group, and 46 patients who underwent Re-TURBT were as observation group. All patients were treated with immediate intravesical instillation with gemcitabine. The positive rate of Re-TURBT and the change of tumor stage and grade were counted, and the tumor recurrence rate and progression rate were analyzed in two groups within 2 years after surgery.

Results

The differences of age, gender, smoking history, maximum tumor size, number of tumors and first postoperative pathology were not statistically difference between the two groups (P>0.05). In observation group, the second postoperative pathological results showed that 11 cases (23.91%) of residual cancers were detected and there were clinical staging upgrades in 5 cases and pathological grading upgrades in 4 cases after surgery. The total recurrence rate of 2 years after surgery was lower than that of the control group (P<0.05). No significant difference in total progress rate in 2 years after surgery (P>0.05).

Conclusions

Re-TURBT combined with gemcitabine immediate intravesical instillation can reduce the tumor recurrence and obtain more accurate tumor stage of T_a and T₁ stage NMIBC, which is of important clinical value.

Key words: Bladder cancer, Gemcitabine, Resection of bladder

Dong Jiang, Yihong Zhou, Lei Mai, Zhenjie Wu, Jianzhong Xian, Yingbo Dai. Efficacy of repeat transurethral resection in the treatment of non-muscle invasive bladder cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(06): 513-517.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2022.06.006

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2022/V16/I06/513

Figures/Tables 5

References 18

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]	Gendy R, Delprdo W, Brenner P, et al. Repeat transurethral resection for non-muscle-invasive bladder cancer:a contemporary series[J]．BJU Int, 2016, 117(Suppl 4): 54-59．
[3]	Miyake M，Morizawa Y，Hori S，et al. Diagnostic and prognostic role of urinary collagens in primary human bladder cancer[J]. Cancer Sci, 2017, 108(11): 2221-2228.
[4]	金佩玉, 孙天水, 席淑华. 影响膀胱癌发生的职业和环境危险因素研究进展[J]. 环境与职业医学, 2017, 34(9): 840-846.
[5]	Dangi AD, Kumar RM，Kodiatte TA, et al. Is there a role for second transurethral resection in pTa high-grade urothelial bladder cancer?[J]. Cent European J Urol, 2018, 71(3): 287-294.
[6]	黄友锋, 张家彬, 刘昌明, 等. 绿激光汽化术联合吡柔比星灌注化疗治疗非肌层浸润性膀胱癌临床观察[J]. 山东医药, 2016, 56(4): 54-55.
[7]	Siegel RL, Miller KD, Jemal A. Cancer statistics [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[8]	Shadpour P, Zamani M, Aghaalikhani N, et al. Inflammatory cytokines in bladder cancer[J]. J Cell Physiol, 2019, 234(4): 14489-14499.
[9]	罗家宇, 郭新权, 王永胜, 等. 再次经尿道膀胱肿瘤电切在非肌层浸润性膀胱癌治疗中的临床价值[J]. 临床泌尿外科杂志, 2020, 35(11): 907-915.
[10]	Angulo JC, Palou J, Gacia-Tello A, et al. Second transurethral resection and prognosis of high-grade non-muscle-invasive bladder cancer in patients not receiving bacillus Calmette-Guerin[J]. Actas Urol Esp, 2014, 38(3): 164-171.
[11]	Gendy R, Delprdo W, Brenner P, et al. Repeat transurethral resection for non-muscle-invasive bladder cancer:a contemporary series[J]. BJU Int, 2016, 117(Suppl 4): 54-59．
[12]	杨诚, 陈伟, 梁朝朝.非肌层浸润性膀胱癌行二次电切术的临床意义及相关危险因素分析[J]. 中华泌尿外科杂志, 2019, 40(7): 498-502.
[13]	Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in Non-muscle-invasive bladder cancer: A systematic review[J]. Eur Urol, 2018, 73(6): 925-933.
[14]	郑铎, 刘隽垚, 岳中瑾,等. 上尿路尿路上皮癌术后膀胱灌注化疗的研究进展[J]. 中华泌尿外科杂志, 2020, 41 (5): 397-400.
[15]	何问理, 温海东, 杨俊, 等.经尿道双极等离子电切术与剜除术治疗非肌层浸润性膀胱癌的病例对照研究[J/CD]. 中华腔镜泌尿外科杂志(电子版) 2019, 13 (3): 162-165.
[16]	郑红淑, 范海涛, 冯树强. 表浅性膀胱癌TURBT术后吉西他滨和吡柔比星交替膀胱灌注预防复发的疗效[J]. 中国老年学, 2015, 36(16): 4579-4580.
[17]	Yumura Y, Takase K, Kato Y, et al. The significance ofurine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence[J]. Hinyokika Kiyo, 2004, 50(3): 171-176．
[18]	廖义翔, 周家杰, 杨光华, 等. 吉西他滨在膀胱癌治疗中的应用研究[J]. 现代泌尿生殖肿瘤杂志, 2017, 9(5): 265-268.

组别	例数	年龄[岁，(±s)]	性别（例）		吸烟史（例）		肿瘤最大径[cm，(±s)]	肿瘤个数(个)	首次电切病理分期（例）
组别	例数	年龄[岁，(±s)]	男	女	有	无	肿瘤最大径[cm，(±s)]	肿瘤个数(个)	T_a	T₁
对照组	40	47±13	31	9	29	11	2.0±1.3	2.4±1.2	32	8
观察组	46	48±14	35	11	31	15	2.1±1.2	2.3±1.2	37	9
统计值		t=-0.348	χ²=0.024		χ²=0.265		t=-0.261	t=0.188	χ²=0.020
P值		0.729	0.877		0.607		0.794	0.851	0.887

组别	例数	年龄[岁，(±s)]	性别（例）		吸烟史（例）		肿瘤最大径[cm，(±s)]	肿瘤个数(个)	首次电切病理分期（例）
组别	例数	年龄[岁，(±s)]	男	女	有	无	肿瘤最大径[cm，(±s)]	肿瘤个数(个)	T_a	T₁
对照组	40	47±13	31	9	29	11	2.0±1.3	2.4±1.2	32	8
观察组	46	48±14	35	11	31	15	2.1±1.2	2.3±1.2	37	9
统计值		t=-0.348	χ²=0.024		χ²=0.265		t=-0.261	t=0.188	χ²=0.020
P值		0.729	0.877		0.607		0.794	0.851	0.887

组别	≤6个月	7~12个月	13~24个月	总复发率
对照组	4（10.00）	7（17.50）	10（25.00）	21（52.50）
观察组	2（4.35）	4（8.70）	7（15.22）	13（28.26）
χ²值				5.670
P值				0.017

组别	≤6个月	7~12个月	13~24个月	总复发率
对照组	4（10.00）	7（17.50）	10（25.00）	21（52.50）
观察组	2（4.35）	4（8.70）	7（15.22）	13（28.26）
χ²值				5.670
P值				0.017

组别	≤6个月	7~12个月	13~24个月	总进展率
对照组	2（5.00）	3（7.50）	4（10.00）	9（22.50）
观察组	2（4.35）	3（6.52）	3（6.52）	8（17.39）
χ²值				0.352
P值				0.553

Please choose a citation manager

Content to export